Bevacizumab Fails to Improve 3-Year Survival in Early Colon Cancer


Dr. Norman Wolmark explains his team's large, much-anticipated study showing that bevacizumab failed to make a significant improvement in disease-free survival at 3 years for early-stage colon cancer. Dr. Wolmark, chairman of Human Oncology, Allegheny General Hospital in Pittsburgh, presented the findings at the annual meeting of the American Society of Clinical Oncology.

Next Article: